{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:22:17Z","timestamp":1784647337348,"version":"3.55.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.amjms.2016.05.003","type":"journal-article","created":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T17:04:14Z","timestamp":1462813454000},"page":"177-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome"],"prefix":"10.1016","volume":"352","author":[{"given":"Bruce E.","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2016.05.003_bib1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/adc.40.214.654","article-title":"Fatal haemolytic uraemic syndrome and idiopathic hyperlipaemia in monozygotic twins","volume":"40","author":"Campbell","year":"1965","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.amjms.2016.05.003_bib2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0034-1376153","article-title":"Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches","volume":"40","author":"Riedl","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.amjms.2016.05.003_bib3","first-page":"110","article-title":"Hypocomplementaemia due to a genetic deficiency of beta 1H globulin","volume":"46","author":"Thompson","year":"1981","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Farhouk","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib5","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00467-008-0872-4","article-title":"Complement and the atypical hemolytic uremic syndrome in children","volume":"23","author":"Loirat","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib6","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.amjms.2016.05.003_bib8","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.2215\/CJN.07540714","article-title":"Factors influencing treatment of atypical hemolytic uremic syndrome","volume":"9","author":"Nester","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/0046-8177(92)90127-O","article-title":"A congenital anomaly of vitamin B12 metabolism: a study of three cases","volume":"23","author":"Russo","year":"1992","journal-title":"Hum Pathol"},{"key":"10.1016\/j.amjms.2016.05.003_bib10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genetics"},{"key":"10.1016\/j.amjms.2016.05.003_bib11","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-06-579953","article-title":"Loss of DGK\u03b5 induces endothelial cell activation and death independently of complement activation","volume":"125","author":"Bruneau","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.05.003_bib12","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2016.05.003_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2016.05.003_bib15","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2215\/CJN.01640214","article-title":"Complement mutations in diacylglycerol kinase-\u03b5-associated atypical hemolytic uremic syndrome","volume":"9","author":"Chinchilla","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib16","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2215\/CJN.08520814","article-title":"Characterization of a new DGKE intronic mutation in genetically unsolved cases of familial atypical hemolytic uremic syndrome","volume":"10","author":"Mele","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical aHUS: state of the art","volume":"67","author":"Nester","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib18","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1681\/ASN.V2111640","article-title":"Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome","volume":"2","author":"Schieppati","year":"1992","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1042\/BSR20140117","article-title":"New functional and structural insights from updated mutational databases for complement factor H, factor I, membrane cofactor protein and C3","volume":"34","author":"Rodriguez","year":"2014","journal-title":"Biosci Rep"},{"key":"10.1016\/j.amjms.2016.05.003_bib20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetic of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.amjms.2016.05.003_bib21","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.amjms.2016.05.003_bib22","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2215\/CJN.02790313","article-title":"Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN","volume":"8","author":"Gou","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib23","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/blood-2010-05-283564","article-title":"Complement alternate pathway acts as a positive feedback amplification of neutrophil activation","volume":"117","author":"Camous","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.05.003_bib24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00467-014-2944-y","article-title":"Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy","volume":"30","author":"Coppo","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib25","doi-asserted-by":"crossref","first-page":"1002079","DOI":"10.1371\/journal.pgen.1002079","article-title":"Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility","author":"Zhao","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.amjms.2016.05.003_bib26","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Ecuilzumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.amjms.2016.05.003_bib27","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.05.003_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrneph.2014.38","article-title":"Renal involvement in antiphospholipid syndrome","volume":"10","author":"Sciascia","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib29","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizumab and renal transplantation in a patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2016.05.003_bib30","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.00860115","article-title":"Drug-induced glomerular disease: direct cellular injury","author":"Markowitz","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib31","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1182\/blood-2013-03-487694","article-title":"Complement factor H mutations are present in ADAMTS13-deficient, ticlopidone-associated thrombotic microangiopathies","volume":"121","author":"Chapin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.05.003_bib32","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1182\/blood-2013-07-512707","article-title":"TMA: beware of complements","volume":"122","author":"Ricklin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.05.003_bib33","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1160\/TH04-07-0450","article-title":"Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies","volume":"93","author":"Ruiz-Torres","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjms.2016.05.003_bib35","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1681\/ASN.2007010062","article-title":"Is there a shared pathophysiology for thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome?","volume":"18","author":"Desch","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib36","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09084.x","article-title":"Eculizimab in the treatment of refractory idiopathic thrombotic thromobocytopenic purpura","volume":"157","author":"Chapin","year":"2012","journal-title":"Br J Haemotol"},{"key":"10.1016\/j.amjms.2016.05.003_bib37","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1309\/AJCPXPD7ZQXNTIAL","article-title":"Effect of blood sampling, processing, and storage on the measurement of complement activation biomarkers","volume":"143","author":"Yang","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.amjms.2016.05.003_bib38","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1055\/s-0034-1383547","article-title":"Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway","volume":"40","author":"Turner","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.amjms.2016.05.003_bib39","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4049\/jimmunol.176.3.1305","article-title":"The central role of the alternative complement pathway in human disease","volume":"176","author":"Thurman","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","article-title":"The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation","volume":"138","author":"Harboe","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1269","article-title":"The dark side of C5a in sepsis","volume":"4","author":"Ward","year":"2004","journal-title":"Nature Rev Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1681\/ASN.2010111145","article-title":"Targeting complement C5 in atypical hemolytic uremic syndrome","volume":"22","author":"Salant","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib43","doi-asserted-by":"crossref","first-page":"E97","DOI":"10.1111\/petr.12450","article-title":"Hematopoietic stem cell transplantation-associated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition","volume":"19","author":"Sakamoto","year":"2015","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.amjms.2016.05.003_bib44","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/302673","article-title":"Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome","volume":"65","author":"Ying","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.amjms.2016.05.003_bib45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/adc.53.3.255","article-title":"Familial haemolytic syndrome","volume":"53","author":"Edelstein","year":"1978","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.amjms.2016.05.003_bib46","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1046\/j.1365-2249.1996.d01-777.x","article-title":"Heterozygous and homozygous factor H deficiency states in a Dutch family","volume":"105","author":"Fijen","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib47","first-page":"119","article-title":"The successful treatment of atypical hemolytic uremic syndrome with plasmapheresis","volume":"35","author":"Robson","year":"1991","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib48","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome","volume":"53","author":"Warwicker","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2016.05.003_bib49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldl004","article-title":"Atypical haemolytic uraemic syndrome","volume":"77-78","author":"Kavanagh","year":"2006","journal-title":"Br Med Bull"},{"key":"10.1016\/j.amjms.2016.05.003_bib50","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2016.05.003_bib51","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib52","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","article-title":"Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome","volume":"24","author":"Ariceta","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib53","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.2.4790.897","article-title":"Thrombotic microangiopathic hemolytic anemia (thrombotic microangiopathy)","volume":"2","author":"Symmers","year":"1952","journal-title":"Br Med J"},{"key":"10.1016\/j.amjms.2016.05.003_bib54","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/blood.V87.10.4235.bloodjournal87104235","article-title":"Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion","volume":"87","author":"Tsai","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.05.003_bib55","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member in the ADAMTS13 gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.amjms.2016.05.003_bib56","doi-asserted-by":"crossref","first-page":"834","DOI":"10.5858\/2003-127-834-TTPAHU","article-title":"Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities","volume":"127","author":"Hosler","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.amjms.2016.05.003_bib57","first-page":"21","article-title":"An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease","volume":"24","author":"Moschcowitz","year":"1924","journal-title":"Proc NY Pathol Sci"},{"key":"10.1016\/j.amjms.2016.05.003_bib58","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1084\/jem.154.3.856","article-title":"Formation of the initial C3 convertase of the alternative complement pathway","volume":"154","author":"Pangburn","year":"1981","journal-title":"J Exp Med"},{"key":"10.1016\/j.amjms.2016.05.003_bib59","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1471-2369-15-82","article-title":"Properdin has an ascendancy over factor H regulation in complement-mediated renal tubular damage","volume":"15","author":"Nagamachi","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib60","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.imbio.2012.07.016","article-title":"Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy","volume":"217","author":"Ricklin","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.amjms.2016.05.003_bib61","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.imbio.2012.07.008","article-title":"The tick-over theory revisited: Is C3 a contact-activated protein?","volume":"217","author":"Nilsson","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.amjms.2016.05.003_bib62","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib63","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1016\/j.molimm.2008.06.034","article-title":"Properdin: new roles in pattern recognition and target clearance","volume":"45","author":"Kemper","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib64","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00251-006-0142-1","article-title":"Genomic view of the evolution of the complement system","volume":"58","author":"Nonaka","year":"2006","journal-title":"Immunogenetics"},{"key":"10.1016\/j.amjms.2016.05.003_bib65","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.4049\/jimmunol.1200357","article-title":"Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor H and factor-H related protein 1 to pentraxin 3","volume":"189","author":"Kopp","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib66","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.4049\/jimmunol.153.5.2213","article-title":"Antibody-mediated complement activation on nucleated cells: a quantitative analysis of the individual reaction steps","volume":"153","author":"Ollert","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib67","first-page":"21","article-title":"The complement C3 protein family in invertebrates","volume":"8","author":"Nonaka","year":"2011","journal-title":"Invert Surviv J"},{"key":"10.1016\/j.amjms.2016.05.003_bib68","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/978-0-387-71767-8_26","article-title":"Ancient origin of the complement system: emerging invertebrate models","volume":"598","author":"Pinto","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.amjms.2016.05.003_bib69","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res"},{"key":"10.1016\/j.amjms.2016.05.003_bib70","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1074\/jbc.M508928200","article-title":"The role of properdin in the assembly of the alternative pathway C3 convertases of complement","volume":"281","author":"Hourcade","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjms.2016.05.003_bib71","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ajhg.2011.05.011","article-title":"Disease-causing mutations in genes of the complement system","volume":"88","author":"Degn","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.amjms.2016.05.003_bib72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-065X.1998.tb01249.x","article-title":"The phylogeny and evolution of the thioester bond-containing proteins C3, C4 and \u03b12-macroglobulin","volume":"166","author":"Dodds","year":"1998","journal-title":"Immunol Rev"},{"key":"10.1016\/j.amjms.2016.05.003_bib73","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/biom2010046","article-title":"A complement regulator in health and disease, and a mediator of cellular interactions","volume":"2","author":"Kopp","year":"2012","journal-title":"Biomolecules"},{"key":"10.1016\/j.amjms.2016.05.003_bib74","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1084\/jem.20070664","article-title":"Complement factor H and the hemolytic uremic syndrome","volume":"204","author":"Atkinson","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.amjms.2016.05.003_bib75","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1084\/jem.142.4.856","article-title":"Properdin: binding to C3b and stabilization of the C3b-dependent C3 Convertase","volume":"142","author":"Fearon","year":"1975","journal-title":"J Exp Med"},{"key":"10.1016\/j.amjms.2016.05.003_bib76","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4049\/jimmunol.179.4.2600","article-title":"Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly","volume":"179","author":"Spitzer","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib77","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.molimm.2014.07.004","article-title":"Complement Nomenclature 2014","volume":"61","author":"Kemper","year":"2014","journal-title":"Mol Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib78","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ejim.2013.05.009","article-title":"Complement activation in diseases presenting with thrombotic microangiopathy","volume":"24","author":"Meri","year":"2013","journal-title":"Eur J Int Med"},{"key":"10.1016\/j.amjms.2016.05.003_bib79","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1126\/science.120.3112.279","article-title":"The properdin system and immunity: demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena","volume":"120","author":"Pillemer","year":"1954","journal-title":"Science"},{"key":"10.1016\/j.amjms.2016.05.003_bib80","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1353\/pbm.1980.0036","article-title":"A war with the molecules: Louis Pillemer and the history of properdin","volume":"100","author":"Ratnoff","year":"1980","journal-title":"Perspect Biol Med"},{"key":"10.1016\/j.amjms.2016.05.003_bib81","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4049\/jimmunol.125.2.471","article-title":"Louis Pillemer, properdin, and scientific controversy","volume":"125","author":"Lepow","year":"1980","journal-title":"J Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib82","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4049\/jimmunol.100.1.142","article-title":"Properties of highly purified human properdin","volume":"100","author":"Pensky","year":"1968","journal-title":"J Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib83","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1042\/bj2350723","article-title":"The C3 convertase of the alternative pathway of human complement","volume":"235","author":"Pangburn","year":"1986","journal-title":"Biochem J"},{"key":"10.1016\/j.amjms.2016.05.003_bib84","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1084\/jem.152.4.1102","article-title":"Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement","volume":"152","author":"Pangburn","year":"1980","journal-title":"J Exp Med"},{"key":"10.1016\/j.amjms.2016.05.003_bib85","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/adc.51.2.91","article-title":"Defective opsonization: a common immunity deficiency","volume":"51","author":"Soothill","year":"1976","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.amjms.2016.05.003_bib86","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clim.2005.10.014","article-title":"Membrane complement regulatory proteins","volume":"118","author":"Kim","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib87","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1073\/pnas.73.9.3268","article-title":"Control of the amplification convertase by the plasma protein \u03b21H","volume":"73","author":"Weiler","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.amjms.2016.05.003_bib88","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1681\/ASN.2013121339","article-title":"A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1\/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation","volume":"26","author":"Valoti","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib89","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0034-1375296","article-title":"Genetics of atypical hemolytic uremic syndrome (aHUS)","volume":"40","author":"De C\u00f3rdoba","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.amjms.2016.05.003_bib90","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/asheducation-2011.1.15","article-title":"Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations","volume":"2011","author":"Kavanagh","year":"2011","journal-title":"Hematology"},{"key":"10.1016\/j.amjms.2016.05.003_bib91","doi-asserted-by":"crossref","first-page":"c219","DOI":"10.1159\/000276545","article-title":"Atypical hemolytic uremic syndrome: update on the complement system and what is new","volume":"114","author":"Hirt-Minkowski","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.amjms.2016.05.003_bib92","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.4049\/jimmunol.1201751","article-title":"Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions","volume":"190","author":"Clark","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib93","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMra1108178","article-title":"Membranoproliferative glomerulonephritis\u2014a new look at an old entity","volume":"366","author":"Sethi","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2016.05.003_bib94","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ki.2012.212","article-title":"C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up","volume":"82","author":"Sethi","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2016.05.003_bib95","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2016.05.003_bib96","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.molimm.2015.03.011","article-title":"Of mice and men: the factor H protein family and complement regulation","volume":"67","author":"Pouw","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib97","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1084\/jem.20070301","article-title":"Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking recognition domains","volume":"204","author":"Pickering","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.amjms.2016.05.003_bib98","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010050451","article-title":"The development of atypical hemolytic uremic syndrome depends on complement C5","volume":"22","author":"De Jorge","year":"2011","journal-title":"J Am Soc Neph"},{"key":"10.1016\/j.amjms.2016.05.003_bib99","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2012-02-412080","article-title":"Thrombin generates previously unidentified C% products that support the terminal complement activation pathway","volume":"120","author":"Krisinger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.05.003_bib100","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ejim.2013.05.007","article-title":"Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic micoangiopathies","volume":"24","author":"Cataland","year":"2013","journal-title":"Eur J Int Med"},{"key":"10.1016\/j.amjms.2016.05.003_bib101","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nrneph.2013.280","article-title":"Cardiovascular complications in atypical haemolytic uraemic syndrome","volume":"10","author":"Noris","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib102","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/ndt\/gfq160","article-title":"Myocardial infarction is a complication of factor H-associated atypical HUS","volume":"25","author":"Sall\u00e9e","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjms.2016.05.003_bib103","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib104","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib105","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS and TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.05.003_bib106","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.05.003_bib107","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2014-07-590356","article-title":"COMPLEMENTing the diagnosis of aHUS","volume":"124","author":"Afshar-Khargan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.05.003_bib108","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/trf.12885","article-title":"Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why?","volume":"55","author":"George","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.amjms.2016.05.003_bib109","doi-asserted-by":"crossref","DOI":"10.1111\/cei.12426","article-title":"Complement activation patterns in atypical hemolytic uremic syndrome during acute phase and in remission","author":"Volokhina","year":"2015","journal-title":"Clin Exp Immun"},{"key":"10.1016\/j.amjms.2016.05.003_bib110","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1053\/j.ajkd.2015.02.326","article-title":"Soluble C5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome","volume":"65","author":"Bu","year":"2015","journal-title":"Am J Kid Dis"},{"key":"10.1016\/j.amjms.2016.05.003_bib111","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1309\/AJCPXPD7ZQXNTIAL","article-title":"Effect of blood sampling, processing, and storage on the measurement of complement activation","volume":"143","author":"Yang","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.amjms.2016.05.003_bib112","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.05.003_bib113","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2014050429","article-title":"Complement factor C4d is a common denominator in thrombotic microangiopathy","author":"Chua","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib114","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jth.12615","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome","volume":"12","author":"Cugno","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjms.2016.05.003_bib115","first-page":"1371","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"10","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.amjms.2016.05.003_bib116","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2012.09032.x","article-title":"The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies","volume":"157","author":"Cataland","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.amjms.2016.05.003_bib117","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1537-2995.2010.02653.x","article-title":"The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange","volume":"50","author":"Bentley","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.amjms.2016.05.003_bib118","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjh.12707","article-title":"Complement and cytokine response in acute thrombotic thrombocytopenic purpura","volume":"164","author":"Westwood","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.amjms.2016.05.003_bib119","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1111\/jth.12369","article-title":"Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura","volume":"11","author":"Wu","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjms.2016.05.003_bib120","first-page":"1081","article-title":"The origin of P-selectin as a circulating plasma protein","volume":"77","author":"Fijnheer","year":"1977","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjms.2016.05.003_bib121","first-page":"3","article-title":"Increased P-selectin plasma levels in patients with thrombotic thrombocytopenic purpura","volume":"81","author":"Vianelli","year":"1996","journal-title":"Haematologica"},{"key":"10.1016\/j.amjms.2016.05.003_bib122","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.molimm.2010.05.009","article-title":"Complement activation on platelets: implications for vascular inflammation and thrombosis","volume":"47","author":"Peerschke","year":"2010","journal-title":"Mol Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib123","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood.V83.6.1535.1535","article-title":"Plasma P-selectin is increased in thrombotic consumptive platelet disorders","volume":"83","author":"Chong","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.05.003_bib124","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.05.003_bib125","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"issue":"S15","key":"10.1016\/j.amjms.2016.05.003_bib126","first-page":"2","article-title":"Atypical hemolytic uremic syndrome (aHUS): treating the patient","volume":"11","author":"Laurence","year":"2013","journal-title":"Clin Adv Hemat"},{"key":"10.1016\/j.amjms.2016.05.003_bib127","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2014.07.031","article-title":"Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab","volume":"65","author":"El-Husseini","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2016.05.003_bib128","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","author":"Loirat","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib129","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/j.ajkd.2012.07.028","article-title":"Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab","volume":"61","author":"Schmidtko","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2016.05.003_bib130","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.4049\/jimmunol.160.12.6128","article-title":"Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction","volume":"160","author":"Hindmarsh","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.amjms.2016.05.003_bib131","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00467-014-2790-y","article-title":"Proteomic urinary biomarker approach in renal disease: from discovery to implementation","volume":"30","author":"Schanstra","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.amjms.2016.05.003_bib132","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/ki.2015.60","article-title":"Managing atypical hemolytic uremic syndrome: chapter 2","volume":"87","author":"Nester","year":"2015","journal-title":"Kidney Int"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915379374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915379374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T04:26:58Z","timestamp":1692332818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915379374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":132,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0002962915379374"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2016.05.003","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2016.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Southern Society for Clinical Investigation. Published by All rights reserved.","name":"copyright","label":"Copyright"}]}}